Trial Profile
A 24 week, multicenter, randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of donepezil hydrochloride (E2020) in patients with severe Alzheimer's disease followed by a 12 week open-label extension period
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Apr 2011
Price :
$35
*
At a glance
- Drugs Donepezil (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 22 Oct 2005 New trial record.